GLC1C: A Potential Drug Target for Glaucoma (G2723)

Target Name: GLC1C

NCBI ID: G2723

GLC1C

Other Name(s): Glaucoma 1, open angle, C | glaucoma 1, open angle, C

GLC1C: A Potential Drug Target for Glaucoma

Glaucoma is a leading cause of vision loss worldwide, affecting over 2 million people in the United States alone. The two main forms of glaucoma are open-angle glaucoma and closed-angle glaucoma, which are characterized by the degree of damage to the optic nerve. Open-angle glaucoma, also known as GLC1C or normal-tension glaucoma, is the most common form of the disease and is characterized by a slow, gradual increase in the pressure on the optic nerve.

GLC1C is a drug target (or biomarker) that has been identified as a potential treatment for open-angle glaucoma. The GLC1C gene is a single-nucleotide polymorphism (SNP) that has been identified in a significant number of individuals with open-angle glaucoma. The GLC1C gene encodes a protein called GLC1C, which is a key regulator of the aqueous humor fluid (AHF) production and delivery in the eye.

Studies have shown that individuals with GLC1C SNP are more likely to develop open-angle glaucoma than those without the mutation. Additionally, individuals with GLC1C SNP have been shown to have reduced levels of AHF in their eye, which is a key indicator of the progressive damage to the optic nerve.

GLC1C has also been shown to be a potential biomarker for the disease. The AHF is a unique and dynamic environment that is capable of providing essential nutrients and protective factors to the retina, and is a key factor in maintaining retinal health. Therefore, changes in the AHF levels, such as those caused by GLC1C SNP, can be an indication of the progressive damage to the retina.

One of the key advantages of GLC1C as a drug target is its potential to target a specific protein without affecting other proteins in the eye. This can reduce the risk of unintended side effects and improve the overall safety of the treatment. Additionally, GLC1C is a relatively small protein, which makes it easier to manipulate and study its effects.

In conclusion, GLC1C is a promising drug target (or biomarker) for the treatment of open-angle glaucoma. The identification of GLC1C SNP as a risk factor for the disease and its potential as a drug target underscores the importance of further research in this area. Further studies are needed to determine the exact role of GLC1C in the development and progression of open-angle glaucoma, as well as its potential as a biomarker for the disease.

Protein Name: Glaucoma 1, Open Angle, C

The "GLC1C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLC1C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets